SAE |
Severe adverse event |
AE |
adverse event |
SF |
Shortening fraction |
MAPK |
Mitogen activated protein kinase |
NF1 |
Neurofibromatosis type 1 |
LGG |
Low grade gliomas |
HGG |
High grade gliomas |
LCH |
Langerhance cell histiocytosis |
MAKER |
MEK inhibitors associated retinopathy |
BMI |
Boddy mass index |
JPA |
Juvenile pilocytic astrocytoma |
GBM |
Glioblastoma multiforme |
PXA |
Pleomorphic Xanthoastrocytoma |
PLEVA |
Pityriasis Lichenoides et Variolifomis acuta |
SCC |
Squamous cell carcinoma |
GH |
Growth hormone |
DEXA |
Dual energy Xray absorptiometry |
TBS |
Trabecular bone score |
LVSF |
Left ventricular fractional shortening |
AMN |
Acute macular neuroretinopathy |
OCT |
Optical coherence tomography |
EN |
Erythema nodosum |
N# |
NUMBER |